

Product Datasheet

GNE-7883

Catalog No. **BP-02039** · CAS **2648450-42-2** · Form **free base** · Physical state **other** · Color **White to light yellow** · Version **1.0**
· Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target YAP	Research area Cancer
----------------------	--------------------------------

Molecular formula **C₂₈H₂₉FN₆O₂**

Molecular weight **500.5673**

STRUCTURE



DESCRIPTION

GNE-7883 (GNE7883) is a potent, reversible, allosteric inhibitor of the YAP1-TEAD interaction.

BIOLOGICAL ACTIVITY

GNE-7883 (GNE7883) is a potent, reversible, allosteric inhibitor of the YAP1-TEAD interaction. The potent inhibition of pan-TEAD lipidation with GNE-7883 translated well to the disruption of YAP1 binding to each of the four TEAD isoforms by the YAP1 HTRF assay. GNE-7883 potently inhibited proliferation of the OVCAR-8 and NCI-H226 cells, with EC₅₀ values of 115 nM and 333 nM, respectively. GNE-7883 (250 mg/kg, subcutaneous dosing) showed strong in vivo tumor growth inhibition (TGI) of 102% in the mesothelioma NCIH226 xenograft mouse model.

SOLUBILITY

Soluble in DMSO

In vitro DMSO : 50 mg/mL

REFERENCES

- [1]. Holden, Jeffrey K et al. "Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling." Cell reports vol. 31,12 (2020): 107809.
- [2]. Barry ER, Simov V, Valtingoier I, Venier O. Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine. Cells. 2021 Oct 11;10(10):2715. PMID: 34685695; PMCID: PMC8534579.